The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines

The CD37 targeting radioimmunoconjugate 177Lu-lilotomab satetraxetan (Betalutin) is currently being evaluated in a clinical phase 2b trial for patients with follicular lymphoma (FL) and in a phase 1 trial for patients with diffuse large B-cell lymphoma (DLBCL). Herein we have investigated the effect...

Full description

Bibliographic Details
Main Authors: Gro Elise Rødland, Katrine Melhus, Roman Generalov, Sania Gilani, Francesco Bertoni, Jostein Dahle, Randi G. Syljuåsen, Sebastian Patzke
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-11-01
Series:Frontiers in Oncology
Subjects:
radioimmunotherapy (RIT)
CD37
combination therapy
lymphoma
radiation resistance
aurora kinase
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01301/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.01301/full

Similar Items